China Blood Product Industry Report, 2018-2022
  • Feb.2018
  • Hard Copy
  • USD $3,400
  • Pages:170
  • Single User License
    (PDF Unprintable)       
  • USD $3,200
  • Code: ZLC064
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,800
  • Hard Copy + Single User License
  • USD $3,600

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2016, representing a year-on-year rise of 20.4%. After high growth in 2016, the lot release decelerated in 2017 due to two-invoice system (one invoicing for “from pharmaceutical company to primary dealer”, and the other invoicing for “from dealers to hospitals”) with full-year quantity standing at 64.29 million bottles, being on a par with the year-ago level.

Human albumin registered lot release volume of 38.95 million bottles and human immunoglobulin (pH4) for intravenous injection 10.07 million bottles in 2017, down 0.9% and 7.5% from a year ago, respectively, largely due to a slow-down in lot release caused by failure of Gansu Institute of Biological Products in disclosing data on lot release volume of blood products and two-invoice system. Meanwhile, the lot release volume of human prothrombin complex, human hepatitis B immunoglobulin (pH4) for intravenous injection, and human rabies immunoglobulin soared by 26.8%, 46.7% and 36.8%, respectively.

There are over 30 blood product manufacturers in a less concentrated industry in China. Among them, China Biologic Products, Hualan Biological Engineering, Shanghai RAAS Blood Products and Beijing Tiantan Biological Products are more competitive, as they have richer blood product lines and adequate supply of raw materials from plasma stations.

blood 1_副本.png

In the future, China’s blood product industry will head for the following three aspects:

1. Faster industry integration, higher concentration: over the years, the rising number of M&A cases among Chinese blood product companies gave a boost to industry integration and concentration.

blood 2_副本.png

2. Plasma collection volume and number of plasma stations determine position in industry: number of plasma stations has a direct impact on collection volume, and raw material supply of companies directly hinges on collection volume. In current stage, Beijing Tiantan Biological Products Co., Ltd. has completed assets restructuring, and is hopefully to be the bellwether of the industry for it boasts 49 plasma stations, ranking first in the industry.

3. Companies’ more input on research and development of new products is a boon for higher utilization of plasma: Chinese blood product companies are now racing to develop new products, with the aims of stronger comprehensive strength and higher utilization of plasma to reduce waste.

blood 3_副本.png

The report highlights the following:
20120114.gifAnalysis on development of China blood product industry, including policies, status quo, market structure, supply & demand, market size and competitive landscape;
20120114.gifAnalysis on market segments of China blood product industry, covering human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor VIII, hepatitis B human immunoglobulin, human immunoglobulin, human prothrombin complex and the like;
20120114.gifAnalysis on 15 blood product enterprises, including operation, revenue structure, gross margin, R & D investment, blood product business and development strategy;
20120114.gifSummary & forecast and trends.

1. Overview of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Development of China Blood Product Industry
2.1 Related Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competition Pattern

3. Market Segments of China Blood Product Industry
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Market Structure
3.1.3 Competition Pattern
3.1.4 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Competition Pattern
3.2.3 Prospects
3.3 Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Development Status
3.8.2 Competition Pattern

4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Development Strategy
4.5 Zhenxing Biopharmaceutical & Chemical
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Customers
4.5.6 R&D and Investment
4.5.7 Blood Products Business
4.5.8 Development Strategy
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Blood Products Business
4.6.7 Development Strategy
4.7 Wuhan ZhongyuanRuide Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Blood Products Business
4.7.4 Development Strategy
4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.8.1 Profile
4.8.2 Blood Products Business
4.9 Shanghai Institute of Biological Products
4.9.1 Profile
4.9.2 Blood Products Business
4.10 Wuhan Institute of Biological Products Co., Ltd.
4.10.1 Profile
4.10.2 Blood Products Business
4.11 Shanxi Kangbao Biological Product
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Beijing Bohui Innovation Technology
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 R&D Investment
4.13.6 Blood Products Business
4.13.7 Hebei Da’an Pharmaceutical
4.13.8 Guangdong Weilun Biological Pharmaceutical
4.14 Weiguang Biological Products
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 R&D Investment
4.14.6 Blood Products Business
4.14.7 Development Strategy
4.15 Nanyue Biopharming Corporation Ltd.
4.15.1 Profile
4.15.2 Blood Products Business

5. Summary and Forecast
5.1 Summary
5.2 Development Trend
5.2.1 Industry Integration Speeds Up, Concentration Rises Further
5.2.2 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.3 Plasma Volume Increases Progressively
5.2.4 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness
5.2.5 Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.6 Downstream Demand Stimulates the Development of the Industry
5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry

Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1989-2017
Development History of China Blood Product Industry
Lot Release Volume of Major Blood Products in China, 2014-2017
Blood Product Structure in China (by Lot Release Volume), 2014-2017
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2017
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2017
Plasma Collection Volume and YoY Growth Rate in China, 2008-2017
Comparison of Blood Products Covered in Drug Catalogue of National Basic Medical Insurance, 2017-2009
Plasma Supply and Demand in China, 2015-2025E
Comparison between the Price (After Cancellation of Limit Price) of Blood Products and the Original Retail Price Ceiling
Market Size of China Blood Product Industry, 2010-2017
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Jan. 2018
Main Products of Major Blood Product Manufacturing Enterprises in China
Revenue of Major Blood Product Enterprises in China, 2013-2017
Net Income of Major Blood Product Enterprises in China, 2013-2017
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2017
Market Share of China Blood Product Industry (by Enterprise), 2015
Market Share of China Blood Product Industry (by Enterprise), 2016
Market Share of China Blood Product Industry (by Enterprise), 2017
Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2017
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2017
Market Share of Human Albumin in China (by Lot Release Volume), 2017
Market Share of Human Albumin in China (by Lot Release Volume), 2016
Human Albumin Sales of Major Human Albumin Enterprises in China, 2013-2017
Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2017
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2017
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2016
Human Immunoglobulin (pH4) for Intravenous Injection Sales of Major Blood Products Enterprises in China, 2013-2017
Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2017
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2017
Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2017
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2017
Lot Release Volume of Human Immunoglobulin in China, 2010-2017
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2017
Lot Release Volume of Human Prothrombin Complex in China, 2010-2017
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2017
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2017
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2017
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2017
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2017
Product Line of CBPO
Revenue and Operating Income of CBPO, 2012-2017
Revenue Breakdown of CBPO (by Product), 2012-2017
Revenue Structure of CBPO (by Product), 2012-2017
Gross Margin of CBPO, 2012-2017
R&D Costs and % of Total Revenue of CBPO, 2012-2017
CBPO’s Products under Research and R&D Process by the end of 2016
Lot Release Volume of Blood Products of CBPO, 2015-2017
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Jan. 2018
Lot Release Volume of Blood Products of Guizhou Taibang Biological Products, 2016-2017
Ownership Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Jan. 2018
Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2016-2017
Ownership Structure of Xi'an Huitian Blood Products
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of 2018
Revenue and Net Income of Hualan Biological Engineering, 2013-2017
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2017
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2017
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2017
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2017
Category and Specification of Blood Products of Hualan Biological Engineering
Revenue of Blood Products of Hualan Biological Engineering, 2013-2017
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2017
Revenue and Net Income of Hualan Biological Engineering, 2016-2022E
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2017
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2017
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2017
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2017
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2017
R&D Costs of Shanghai RAAS Blood Products, 2013-2017
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Lot Release Volume of Blood Products of Shanghai RAAS Blood Products, 2015-2017
Revenue and Net Income of Shanghai RAAS Blood Products, 2016-2022E
Revenue and Net Income of Tiantan Biological Products, 2013-2017
Revenue Breakdown of TIANTANBIO (by Product), 2013-2016
Revenue Structure of TIANTANBIO (by Product), 2013-2016
Revenue Breakdown of TIANTANBIO (by Region), 2013-2016
Revenue Structure of TIANTANBIO (by Region), 2013-2016
Gross Margin of TIANTANBIO (by Product), 2013-2016
R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2017
R&D Input of Major Projects of TIANTANBIO, 2016
Progress of Major R&D Projects of TIANTANBIO, by the End of 2016
Main Content of Assets Restructuring of Beijing Tiantan Biological Products
Revenue and Net Income of Chengdu Rongsheng, 2015-2017
Lot Release Volume of Main Blood Products of Chengdu Rongsheng, 2015-2017
Revenue and Net Income of TIANTANBIO, 2017-2022E
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Revenue Breakdown of Zhenxing Biopharmaceutical & Chemical (by Product), 2013-2017
Revenue Structure of Zhenxing Biopharmaceutical & Chemical (by Product), 2013-2017
Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Zhenxing Biopharmaceutical & Chemical’s Sales from Top 5 Customers, 2014-2016
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Use of Funds Raised by Zhenxing Biopharmaceutical & Chemical through Private Issuing of A Shares, 2016
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2014-2017
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2016
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2017
Output, Sales Volume and Inventory of Blood Products of Zhenxing Biopharmaceutical & Chemical, 2013-2016
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2016-2022E
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2017
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2016
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2017
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2017
New Patents of Jiangxi Boya Bio-Pharmaceutical, 2017
Revenue of Jiangxi Boya Bio-Pharmaceutical by Product, 2015-2017
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2017
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2016-2022E
Development Course of ZhongyuanRuide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2016
Main Plasma Collection Stations of ZhongyuanRuide Biological Products, as of Jan. 2018
Lot Release Volume of Blood Products of ZhongyuanRuide Biological Products, 2016-2017
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2017
Plasma Collection Stations of Shanghai Institute of Biological Products as of Jan. 2018
Specification of Main Blood Products of Shanghai Institute of Biological Products
Lot Release Volume of Blood Products of Shanghai Institute of Biological Products, 2016-2017
Plasma Collection Stations of Wuhan Institute of Biological Products, as of Jan. 2018
Lot Release Volume of Blood Products of Wuhan Institute of Biological Products, 2016-2017
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Jan. 2018
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2017
Plasma Collection Stations of Green Cross China as of Jan. 2018
Lot Release Volume of Blood Products of Green Cross China, 2016-2017
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2017
Revenue of Beijing Bohui Innovation Technology by Product, 2014-2017
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2017
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2017
R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2017 
Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, as of 2017H1
Major Blood Products of Beijing Bohui Innovation Technology
Output, Sales Volume and Inventory of Blood Products of Beijing Bohui Innovation Technology, 2015-2016
Plasma Collection Stations of Hebei Da’an Pharmaceutical, as of Jan. 2018
Revenue and Net Income of Hebei Da’an Pharmaceutical, 2015-2017
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2017
Plasma Collection Stations of Guangdong Weilun Biological Pharmaceutical, as of Jan.2018
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2017
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2017
Revenue Breakdown and Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2017
Revenue Breakdown and Structure of Shenzhen Weiguang Biological Products (by Region), 2014-2016
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2016
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2016
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2017
R&D Process of Products under Research of Shenzhen Weiguang Biological Products, as of 2017H1
Fundraising Projects of Shenzhen Weiguang Biological Products, 2017
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2017H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2016
Capacity, Output and Sales Volume of Major Products of Shenzhen Weiguang Biological Products, 2014-2016
Average Sales Price of Major Products of Shenzhen Weiguang Biological Products, 2014-2016
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2017
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2016-2022E
Plasma Collection Stations of Nanyue Biopharming, as of Jan.2018
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2017
Market Size of Blood Products in China, 2017-2022E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2017
Plasma Collection Volume and YoY Change in China, 2017-2022E
R&D Investments of Major Chinese Blood Product Enterprises, 2013-2017
New Products Being Developed of Major Chinese Blood Product Enterprises

China Contract Research Organization (CRO) Industry Report, 2020-2026

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the prolife...

China Human Vaccine Industry Report, 2020-2026

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impa...

China Pharmaceutical Distribution Industry Report, 2019-2026

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmace...

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号